Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.


The anti-angiogenic class of drugs is one of the few where representatives have gained international approval for clinical use in oncology during the past decade. Most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets vascular endothelial growth factor (VEGF) and its related pathways. However, the… (More)
DOI: 10.1016/j.drudis.2011.08.007


5 Figures and Tables


Citations per Year

Citation Velocity: 6

Averaging 6 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.